GRI Bio (NASDAQ:GRI) Stock Rating Lowered by Wall Street Zen

GRI Bio (NASDAQ:GRI) was downgraded by Wall Street Zen to a “strong sell” rating in a note issued to investors on Saturday.

A number of other brokerages have also weighed in on GRI. Weiss Ratings reiterated a “sell (e+)” rating on shares of GRI Bio in a research report on Thursday, January 22nd. Ascendiant Capital Markets boosted their price objective on shares of GRI Bio from $980.00 to $1,008.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $644.00.

GRI Bio Stock Down 1.8%

Shares of NASDAQ GRI opened at $3.26 on Friday. The firm’s fifty day moving average is $19.38 and its 200 day moving average is $38.64. GRI Bio has a 52 week low of $3.16 and a 52 week high of $316.44. The company has a market cap of $1.63 million, a price-to-earnings ratio of -0.39 and a beta of -1.39.

GRI Bio (NASDAQ:GRI) last announced its quarterly earnings results on Friday, November 14th. The company reported ($35.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($31.08) by ($4.76). Equities research analysts anticipate that GRI Bio will post -3.04 earnings per share for the current year.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.